Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Neoplasms 2Melanoma 2Lung Neoplasms 1Locally Advanced Rectal Adenocarcinoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × sotigalimab × Clear all
NCT02482168 2023-12-20

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡